Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise despite higher R&D expenses and a decline in operating margin.
Chargers suffer major blow as star left tackle Rashawn Slater sustains season-ending injury, forcing roster adjustments and raising concerns about the team's prospects.
Gilead Sciences reports strong Q2 results, raises full-year guidance, and sees shares rise despite higher R&D expenses and a decline in operating margin.
Chargers suffer major blow as star left tackle Rashawn Slater sustains season-ending injury, forcing roster adjustments and raising concerns about the team's prospects.